MorphoSys Aktie

39,12EUR
-1,18EUR
-2,93%
22.10.2021

WKN: 663200 / ISIN: DE0006632003

  Kaufen  
Verkaufen
oder
Werbung

MorphoSys Aktien News

04:54 Uhr
FDA says Pfizer COVID vaccine looks effective for young kids (EN, Chinapost)
22.10.21
FDA approves Roche’s Susvimo, a first-of-its-kind therapeutic approach for neovascular or “wet” age-related macular degeneration (nAMD) (Roche Holding AG)
22.10.21
Should You Buy Eli Lilly and Company (LLY) Ahead of Earnings? (Zacks)
22.10.21
Coronavirus Update: Pfizer data boosts hopes children will soon be eligible for COVID-19 vaccine, and CDC expands booster program (MarketWatch)
22.10.21
Fastly, PagerDuty, Johnson & Johnson, Moderna and Pfizer highlighted as Zacks Bull and Bear of the Day (Zacks)
22.10.21
The Zacks Analyst Blog Highlights: Alphabet, Netflix, Thermo Fisher Scientific, Wells Fargo and Novartis (Zacks)
22.10.21
Pfizer says COVID-19 vaccine more than 90% effective in kids (EN, Chinapost)
22.10.21
Dupixent® (dupilumab) is the first biologic to significantly reduce itch and skin lesions in Phase 3 trial for prurigo nodularis, demonstrating the role of type 2 inflammation in this disease (EN, Sanofi-Aventis)
22.10.21
Roche’s VENTANA PD-L1 (SP263) Assay receives FDA approval as a companion diagnostic to identify certain non-small cell lung cancer patients eligible for Tecentriq® (atezolizumab) (Roche Holding AG)
22.10.21
BB BIOTECH AG : BB Biotech AG publishes its interim report (Investegate)
22.10.21
U.S. CDC Advisory Committee Unanimously Recommends Johnson & Johnson COVID-19 Vaccine as a Booster for All Eligible Individuals Who Receive Authorized COVID-19 Vaccines (EN, Johnson & Johnson)
21.10.21
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2021 (EN, Johnson & Johnson)
21.10.21
Coronavirus Update: CDC gathers to discuss which patient groups should get Moderna and J&J COVID-19 vaccine boosters, and Pfizer reports positive results from booster trial (MarketWatch)
21.10.21
Pfizer boosters show 95.6% efficacy against Covid, study finds (Financial Times)
21.10.21
Depuy Synthes And Johnson & Johnson Institute Launch First-Of-Its-Kind In Australia Mobile Training Lab For Velystm Robotic-Assisted Solution (EN, Johnson & Johnson)
21.10.21
Pfizer and BioNTech say Phase 3 trial found booster dose of COVID vaccine had 95.6% efficacy against disease (Market Watch)
21.10.21
Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine (rss)
21.10.21Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine (Businesswire)
21.10.21
BioNTech SE : Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine (Investegate)
21.10.21
Johnson & Johnson COVID-19 Vaccine Booster Shot Authorized for Emergency Use by U.S. FDA (EN, Johnson & Johnson)
20.10.21
FDA expands approval of Dupixent® (dupilumab) to include children aged 6 to 11 years with moderate-to-severe asthma (EN, Sanofi-Aventis)
20.10.21Advisory Committee on Immunization Practices Votes to Recommend Routine Use of Pfizer’s PREVNAR 20™ (Pneumococcal 20-valent Conjugate Vaccine) in Adults (Businesswire)
20.10.21
Top Analyst Reports for Microsoft, Mastercard & Pfizer (Zacks)
20.10.21
Are Investors Undervaluing Pfizer (PFE) Right Now? (Zacks)
20.10.21
Roche (RHHBY) 9M21 Sales Grow on Strong COVID-19 Tests, View Up (Zacks)
20.10.21
QIAGEN (QGEN) New Launch to Aid Global TB Elimination Targets (Zacks)
20.10.21
Brunswick Agricultural Show to host mass vaccination clinic, offering first and second Pfizer jabs (The West Australian)
20.10.21
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in the first nine months - outlook for 2021 raised (Roche Holding AG)
20.10.21
Form 4 59478 (rss)
20.10.21
Form 8-K 875045 (rss)
20.10.21
F. Hoffmann-La Roche Ltd : [Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in the first nine months – outlook for 2021 raised (Investegate)
19.10.21
Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know (Zacks)
19.10.21
Pfizer made hard push for profit in secret vaccine contracts, report says (The Sydney Morning Herald)
19.10.21
Qiagen (QGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
19.10.21
3 Reasons Growth Investors Will Love Qiagen (QGEN) (Zacks)
19.10.21
Tirzepatide results published in The Lancet show superior A1C and body weight reductions compared to insulin glargine in adults with type 2 diabetes with increased cardiovascular risk (EN, Eli Lilly)
19.10.21
Johnson & Johnson Reports Q3 2021 Results (EN, Johnson & Johnson)
19.10.21
Why Johnson & Johnson Will Be a Bigger Winner With Boosters Than Pfizer and Moderna (MotleyFool)
19.10.21Press Release: Global Heart Hub and Novartis -2- (Dow Jones)
19.10.21Press Release: Global Heart Hub and Novartis partner to tackle ASCVD, a global health crisis and world's #1 killer (Dow Jones)
Seite: 123456789...25

MorphoSys News

MorphoSys News: auf dieser Seite finden Sie alle MorphoSys News und Nachrichten zur MorphoSys Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch MorphoSys News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um MorphoSys News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.
Werbung
finanzen.net zero
finanzen.net zero

Oskar

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln